Altered consciousness states and endogenous psychoses: a common molecular pathway? (Q34456793)

2 August 2017

Altered consciousness states and endogenous psychoses: a common molecular pathway? (English)

1 reference

2 August 2017

1 reference

J Ciprian-Ollivier

1

1 reference

PubMed ID

9468359

2 August 2017

M G Cetkovich-Bakmas

series ordinal

2

1 reference

PubMed ID

9468359

2 August 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

2 August 2017

9

1 reference

inferred from page(s)

published in

Schizophrenia Research

1 reference

2 August 2017

28

1 reference

2 August 2017

2-3

1 reference

2 August 2017

257-265

1 reference

Dimethyltryptamine levels in blood of schizophrenic patients and control subjects

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

A test of the transmethylation hypothesis in acute schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

A longitudinal study of urinary excretion of N,N,-dimethyltryptamine in psychotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Hallucinogenic N-Methylated Indolealkylamines in the Cerebrospinal Fluid of Psychiatric and Control Populations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Bufotenin Like Substances in Form of Glucuronide in Schizophrenic and Normal Urines

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Dreams, Hallucinogenic Drug States, and Schizophrenia: A Psychological and Biological Comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

A new metabolic pathway for N,N-dimethyltryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Urinary excretion of free bufotenin by psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Nialamide, an MAO inhibitor, increases urinary excretion of endogenously produced bufotenin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

A Comparison of the Phenomenology of Hallucinogens and Schizophrenia From Some Autobiographical Accounts*

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Selective deficits in visual perception and recognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Schizophrenia: a new approach

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Platelet MAO in schizophrenics: relationship to symptomatology and neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Mass fragmentographic quantification of urinary N,N-dimethyltryptamine and bufotenine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Urinary dimethyltryptamine and psychiatric symptomatology and classification

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Psychotomimetic N -Methylated Tryptamines: Formation in Brain in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Observations on the metabolism of the psychotomimetic indolealkylamines: implications for future clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

The transmethylation and one-carbon cycle hypotheses of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Comparison of psilocin with psilocybin, mescaline and LSD-25

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

Platelet MAO activity in hallucinating and paranoid schizophrenics: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900116-3

7 January 2021

10.1016/S0920-9964(97)00116-3

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

9468359